Cytodyn Inc (CYDY)

[Apollo_]

Can Gilead Dominant 2014 HIV Market Yet Again?

Sales from Gilead's HIV drugs totaled more than $9 billion last year...

In the fourth quarter, Gilead sold $204 million worth of the drug, suggesting Stribild --- approved by the FDA in late 2012 -- could become a blockbuster this year.

Sales of Complera doubled last year to more than $800 million, suggesting it will also eclipse the $1 billion sales mark in 2014. If those two drugs continue to win scripts, Gilead may end up with five blockbuster HIV treatments on the market, including Atripla, Viread, and Truvada.

The development of combination therapies provides Gilead with a long-lasting HIV product portfolio that should allow the company to maintain its leadership for the foreseeable future.

http://www.fool.com/investing/general/2014/03/12/can-gilead-dominate-the-hiv-drug-market-again-in-2.aspx

Botttom Line: New HIV Therapies aren't being developed, only combining current old ones

Monoclonal Antibody PRO 140 offers a REAL alternative therapy - what kind of market share could it garner??